Skip to content

Culturally Adapted Contingency Management

Cultural Adaptation of Contingency Management for Black Adults With Stimulant Use Disorder

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07443332
Enrollment
70
Registered
2026-03-02
Start date
2028-07-01
Completion date
2030-03-01
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stimulant Use Disorders

Brief summary

The purpose of this study is to develop a culturally adapted contingency management (CM) protocol for Black adults with stimulant use disorder.

Detailed description

This project seeks to develop a culturally adapted Contingency Management (CM) intervention for Black adults with stimulant use disorder (StUD). CM is grounded in behavioral economics and involves the use of tangible positive reinforcements to incentivize verifiable pro-health behaviors. There has been a recent surge in fatal stimulant related drug overdoses in the Black community. Black adults in the United States have been experiencing faster rates of overdose deaths, with a rate of 49.5/100,000 in 2022 (1.4 times the rate among White Americans). A resurgence in stimulant use, contamination of community drug supplies with high potency synthetic opioids (HPSO) and a range of structural and social vulnerabilities are major drivers of this unfortunate trend. CM has been shown to be the most effective intervention for StUD as there are no FDA approved medications for this indication. Emerging evidence shows that Black adults who entered treatment with cocaine-positive urines did not show any gains in treatment retention or other clinical outcomes. This observation of disparate health outcomes has informed the urgency to culturally adapt CM for Black population which is at heightened risk given the opioids/stimulant polysubstance fatal overdose. The objective of this research is to develop components of a culturally adapted CM using theoretically and empirically driven approaches. Specific research aims include: 1) Assessment of the target population's behavioral risks, perceived need for prevention, barriers, preferences for intervention and development of components of CM adaptation; 2) production of iterative drafts of the adapted CM and 3.) Pilot randomized controlled trial to examine the short-term efficacy of the adapted CM with the primary outcomes of percent negative urines and longest duration of abstinence during treatment. Aim 3 consists of PI training to deliver the culturally adapted treatment and the culturally adapted treatment will be piloted with the community that the treatment was adapted for over 12 weeks, twice weekly, with a 4 week lead-in phase. Aims 1 and 2 are Observational aims not requiring registration that will inform Aim 3. The focus of this registration is Aim 3.

Interventions

BEHAVIORALCultually Adapted Contingency Management (CM)

Same protocol as basic CM with adaptations incorporated. The adaption will involve the ADAPT-ITT framework and PEN-3 cultural model.

BEHAVIORALBasic Contingency Management (CM)

An escalating schedule of reinforcement for submitting stimulant-negative urine at each clinic visit over the course of the 12 weeks

Sponsors

Yale University
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants are adults with stimulant use disorder who identify as Black/African American.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* participants must self-identify as Black/African American * DSM-5 diagnosis of stimulant use disorder in the past month (30 days)

Exclusion criteria

* individuals who are intoxicated or otherwise unable to provide consent

Design outcomes

Primary

MeasureTime frameDescription
Percent negative urine samplesWeek 12Participants will provide urine samples twice weekly. Percent of negative urines provided will be calculated.
Mean longest duration of abstinenceWeek 12The longest duration of abstinence in days will be measured.

Secondary

MeasureTime frameDescription
Mean treatment retentionBaseline and Week 12.Treatment retention in days will be measured.
Acceptability of Intervention Measure (AIM)Week 12Treatment Acceptability will be measured using the Acceptability of Intervention Measure (AIM), a 4-item measure of perceived intervention acceptability.Total score 1-5 with higher scores indicating greater acceptability.
Feasibility of Intervention Measure (FIM)Week 12Feasibility of intervention measured using Feasibility of Intervention Measure (FIM)- a 4-item instrument to assess perceived intervention feasibility. Total score 1-5 with higher scores indicating greater feasibility.
Client Satisfaction Questionnaire (CSQ-8)Week 12An 8-item, self-report measure developed to assess global satisfaction with health and behavioral health services. Each item is rated on a 4-point Likert scale, producing total scores ranging from 8 to 32, with higher scores indicating greater satisfaction. The instrument evaluates perceived quality of care, extent to which services met the client's needs, overall benefit, and willingness to recommend the service

Countries

United States

Contacts

CONTACTOluwole Jegede, MD, PhD
Oluwole.jegede@yale.edu203-974-7096
CONTACTAlexander Alario, PhD
Alexandra.alario@yale.edu203-903-4603
PRINCIPAL_INVESTIGATOROluwole Jegede, MD, PhD

Yale University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026